vs
美泰（MAT）与Pediatrix Medical Group, Inc.（MD）财务数据对比。点击上方公司名可切换其他公司
美泰的季度营收约是Pediatrix Medical Group, Inc.的1.7倍（$862.2M vs $493.8M），美泰净利率更高（7.1% vs 6.8%，领先0.3%），美泰同比增速更快（4.3% vs -1.7%），过去两年Pediatrix Medical Group, Inc.的营收复合增速更高（-0.1% vs -10.6%）
美泰是美国知名玩具及娱乐企业，旗下影视制作部门美泰影业运营时间为2018年9月6日至2025年6月2日。其前身为2013年10月16日成立的美泰Playground Productions，更早可追溯至美泰娱乐、美泰工作室等集团原有娱乐业务品牌。
Pediatrix Medical Group是美国领先的专科医疗服务提供商，核心业务覆盖母胎医学、新生儿科、儿科心脏病学等儿科亚专科领域，与美国各地医疗机构合作，为女性、新生儿及儿童提供循证专科医疗服务。
MAT vs MD — 直观对比
营收规模更大
MAT
是对方的1.7倍
$493.8M
营收增速更快
MAT
高出6.0%
-1.7%
净利率更高
MAT
高出0.3%
6.8%
两年增速更快
MD
近两年复合增速
-10.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $862.2M | $493.8M |
| 净利润 | $61.0M | $33.7M |
| 毛利率 | 44.9% | — |
| 营业利润率 | — | 9.9% |
| 净利率 | 7.1% | 6.8% |
| 营收同比 | 4.3% | -1.7% |
| 净利润同比 | 251.4% | 10.5% |
| 每股收益（稀释后） | $0.20 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MATMD
| Q1 26 | $862.2M | — | ||
| Q4 25 | $1.8B | $493.8M | ||
| Q3 25 | $1.7B | $492.9M | ||
| Q2 25 | $1.0B | $468.8M | ||
| Q1 25 | $826.6M | $458.4M | ||
| Q4 24 | $1.6B | $502.4M | ||
| Q3 24 | $1.8B | $511.2M | ||
| Q2 24 | $1.1B | $504.3M |
净利润MATMD
| Q1 26 | $61.0M | — | ||
| Q4 25 | $106.2M | $33.7M | ||
| Q3 25 | $278.4M | $71.7M | ||
| Q2 25 | $53.4M | $39.3M | ||
| Q1 25 | $-40.3M | $20.7M | ||
| Q4 24 | $140.9M | $30.5M | ||
| Q3 24 | $372.4M | $19.4M | ||
| Q2 24 | $56.9M | $-153.0M |
毛利率MATMD
| Q1 26 | 44.9% | — | ||
| Q4 25 | 45.9% | — | ||
| Q3 25 | 50.0% | — | ||
| Q2 25 | 50.9% | — | ||
| Q1 25 | 49.4% | — | ||
| Q4 24 | 50.7% | — | ||
| Q3 24 | 53.1% | — | ||
| Q2 24 | 49.2% | — |
营业利润率MATMD
| Q1 26 | — | — | ||
| Q4 25 | 8.0% | 9.9% | ||
| Q3 25 | 21.9% | 13.8% | ||
| Q2 25 | 7.7% | 12.8% | ||
| Q1 25 | -6.4% | 7.0% | ||
| Q4 24 | 9.6% | 7.8% | ||
| Q3 24 | 26.5% | 6.6% | ||
| Q2 24 | 7.7% | -31.3% |
净利率MATMD
| Q1 26 | 7.1% | — | ||
| Q4 25 | 6.0% | 6.8% | ||
| Q3 25 | 16.0% | 14.5% | ||
| Q2 25 | 5.2% | 8.4% | ||
| Q1 25 | -4.9% | 4.5% | ||
| Q4 24 | 8.6% | 6.1% | ||
| Q3 24 | 20.2% | 3.8% | ||
| Q2 24 | 5.3% | -30.3% |
每股收益（稀释后）MATMD
| Q1 26 | $0.20 | — | ||
| Q4 25 | $0.32 | $0.40 | ||
| Q3 25 | $0.88 | $0.84 | ||
| Q2 25 | $0.16 | $0.46 | ||
| Q1 25 | $-0.12 | $0.24 | ||
| Q4 24 | $0.40 | $0.37 | ||
| Q3 24 | $1.09 | $0.23 | ||
| Q2 24 | $0.17 | $-1.84 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $866.0M | $375.2M |
| 总债务越低越好 | $2.3B | $570.5M |
| 股东权益账面价值 | $2.1B | $865.9M |
| 总资产 | $6.3B | $2.2B |
| 负债/权益比越低杠杆越低 | 1.11× | 0.66× |
8季度趋势，按日历期对齐
现金及短期投资MATMD
| Q1 26 | $866.0M | — | ||
| Q4 25 | $1.2B | $375.2M | ||
| Q3 25 | $691.9M | $340.1M | ||
| Q2 25 | $870.5M | $224.7M | ||
| Q1 25 | $1.2B | $99.0M | ||
| Q4 24 | $1.4B | $229.9M | ||
| Q3 24 | $723.5M | $103.8M | ||
| Q2 24 | $722.4M | $19.4M |
总债务MATMD
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | $570.5M | ||
| Q3 25 | $2.3B | $577.2M | ||
| Q2 25 | $2.3B | $583.9M | ||
| Q1 25 | $2.3B | $590.5M | ||
| Q4 24 | $2.3B | $597.1M | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.3B | — |
股东权益MATMD
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.2B | $865.9M | ||
| Q3 25 | $2.3B | $890.7M | ||
| Q2 25 | $2.2B | $833.8M | ||
| Q1 25 | $2.1B | $789.2M | ||
| Q4 24 | $2.3B | $764.9M | ||
| Q3 24 | $2.3B | $732.5M | ||
| Q2 24 | $2.0B | $706.5M |
总资产MATMD
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.6B | $2.2B | ||
| Q3 25 | $6.6B | $2.2B | ||
| Q2 25 | $6.2B | $2.1B | ||
| Q1 25 | $6.2B | $2.0B | ||
| Q4 24 | $6.5B | $2.2B | ||
| Q3 24 | $6.5B | $2.1B | ||
| Q2 24 | $5.9B | $2.0B |
负债/权益比MATMD
| Q1 26 | 1.11× | — | ||
| Q4 25 | 1.04× | 0.66× | ||
| Q3 25 | 1.03× | 0.65× | ||
| Q2 25 | 1.08× | 0.70× | ||
| Q1 25 | 1.10× | 0.75× | ||
| Q4 24 | 1.03× | 0.78× | ||
| Q3 24 | 1.01× | — | ||
| Q2 24 | 1.18× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $114.1M |
| 自由现金流经营现金流 - 资本支出 | $-88.1M | — |
| 自由现金流率自由现金流/营收 | -10.2% | — |
| 资本支出强度资本支出/营收 | 7.6% | — |
| 现金转化率经营现金流/净利润 | — | 3.39× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流MATMD
| Q1 26 | — | — | ||
| Q4 25 | $796.6M | $114.1M | ||
| Q3 25 | $72.0M | $137.3M | ||
| Q2 25 | $-300.1M | $137.2M | ||
| Q1 25 | $24.8M | $-117.5M | ||
| Q4 24 | $862.1M | $133.0M | ||
| Q3 24 | $155.8M | $91.8M | ||
| Q2 24 | $-252.9M | $107.0M |
自由现金流MATMD
| Q1 26 | $-88.1M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
自由现金流率MATMD
| Q1 26 | -10.2% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
资本支出强度MATMD
| Q1 26 | 7.6% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金转化率MATMD
| Q1 26 | — | — | ||
| Q4 25 | 7.50× | 3.39× | ||
| Q3 25 | 0.26× | 1.91× | ||
| Q2 25 | -5.62× | 3.49× | ||
| Q1 25 | — | -5.66× | ||
| Q4 24 | 6.12× | 4.36× | ||
| Q3 24 | 0.42× | 4.72× | ||
| Q2 24 | -4.45× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MAT
暂无分部数据
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
